Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01602341 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of AN2728 Topical Ointment to Treat Adolescents With Atopic Dermatitis
A Phase 2 study of Dermatitis, Atopic, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 86
- Enrollment target
- 17
- Study locations
NCT01602341: Completed Phase 2 study of Dermatitis, Atopic, sponsored by Pfizer.
NCT01602341 is a Phase 2 study of Dermatitis, Atopic that has completed, run by Pfizer. The registered enrollment target is 86 participants, below the 394-participant average among 29 other Dermatitis, Atopic trials with a reported enrollment target (78% lower). The trial reports 17 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01602341, a Phase 2 study of Dermatitis, Atopic, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 86 participants
- Enrollment target
- 17
- Study locations
Study Summary
The purpose of this study is to determine the safety and efficacy of AN2728 Topical Ointment, 2% and 0.5%, administered once a day (QD) or twice a day (BID), in the treatment of adolescents with atopic dermatitis (AD)
Primary Outcome
ADSI was used to assess the severity of atopic dermatitis (AD) based on five subscale scores of erythema, pruritus, exudation, excoriation, and lichenification. The severity of each subscale was measured on a 4-point scale ranging from 0 (none) to 3 (severe), where higher scores indicating more severity. ADSI was calculated as the sum of these 5 subscale scores with a total possible score range of 0 (none) to 15 (most severe) where, higher scores indicating more severity. Improvement from Baseli
Conditions Studied
Interventions
- DRUG AN2728 Topical Ointment, 2% QD
- DRUG AN2728 Topical Ointment, 0.5% QD
- DRUG AN2728 Topical Ointment, 2% BID
- DRUG AN2728 Topical Ointment, 0.5% BID
Study Locations (17)
Victoria
- Anacor Investigational Site - Box Hill
- Anacor Investigational Site - Parkville
California
- Anacor Investigational Site - Fremont
Florida
- Anacor Investigational Site - Miami
Kentucky
- Anacor Investigational Site - Lousiville
Michigan
- Anacor Investigational Site - Detroit
New Mexico
- Anacor Investigational Site - Albuquerque
New York
- Anacor Investigational Site - Stony Brook
North Carolina
- Anacor Investigational Site - High Point
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2012-08 |
| Est. Completion | 2013-01 |
| Phase | Phase 2 |
What the finished NCT01602341 record still lists
NCT01602341 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 86 participants, a relatively small participant target, below the 394-participant average among 29 other Dermatitis, Atopic trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Dermatitis, Atopic appearing as the primary indexed condition, and to 4 interventions - of which AN2728 Topical Ointment, 2% QD is the first listed.
NCT01602341 lists 17 locations in 16 states (Victoria, California, Florida).
Frequently Asked Questions
What is clinical trial NCT01602341 about?
NCT01602341 is a clinical study titled "Efficacy and Safety of AN2728 Topical Ointment to Treat Adolescents With Atopic Dermatitis". The purpose of this study is to determine the safety and efficacy of AN2728 Topical Ointment, 2% and 0.5%, administered once a day (QD) or twice a day (BID), in the treatment of adolescents with atopic dermatitis (AD)
What is the current status of trial NCT01602341?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 86 participants. The study started on 2012-08. Estimated completion is 2013-01.
What conditions does trial NCT01602341 study?
This clinical trial studies the following conditions: Dermatitis, Atopic.
What interventions are being tested in trial NCT01602341?
The interventions under investigation include: AN2728 Topical Ointment, 2% QD (DRUG), AN2728 Topical Ointment, 0.5% QD (DRUG), AN2728 Topical Ointment, 2% BID (DRUG), AN2728 Topical Ointment, 0.5% BID (DRUG).
Who is sponsoring clinical trial NCT01602341?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01602341 being conducted?
This trial has 17 study locations across California, Florida, Kentucky, Michigan, New Mexico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dermatitis, Atopic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01602341's enrollment target sits among peer trials
86 23rd of 29 higher than 7 of 29 other Dermatitis, Atopic trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dermatitis, Atopic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Effects of Treatments on Atopic Dermatitis
RECRUITING · Phase 2
-
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis
ACTIVE NOT RECRUITING · Phase 2
-
Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL)
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01639508 · 86 participants · Phase 2
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
- NCT03519269 · 86 participants · NA
Navio Robotic Versus Conventional Total Knee Arthroplasty
- NCT04132999 · 86 participants · NA
PAP for Children With DS and OSAS
- NCT04545957 · 86 participants · NA
Jump: MR Simulation For Radiation Therapy Master Protocol
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia